SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.97% | 539.11% | -37.88% | -3.40% | 50.15% |
| Total Depreciation and Amortization | -2.85% | -20.83% | -26.61% | -60.79% | -16.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.34% | -6,223.37% | 173.22% | 9.96% | -66.70% |
| Change in Net Operating Assets | -288.28% | -22.54% | 258.07% | 138.37% | -340.88% |
| Cash from Operations | -76.00% | -107.41% | 7.34% | 27.47% | 29.11% |
| Capital Expenditure | -1,584.48% | -- | -- | -- | 18.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.24% | -12,241.43% | -53.88% | 114.96% | -- |
| Cash from Investing | -118.29% | -11,167.47% | -53.67% | 114.90% | 13,841.97% |
| Total Debt Issued | -- | -- | -- | -- | -32.57% |
| Total Debt Repaid | 86.61% | 94.45% | 31.11% | 30.52% | 4.63% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 82.73% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -119.22% | 25,124.33% | 45.86% | 55.88% | -99.68% |
| Foreign Exchange rate Adjustments | -37.82% | -178.95% | 533.92% | 250.18% | -1,695.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6,826.06% | 418.81% | -160.72% | 92.34% | -100.50% |